Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR -Activating Mutations
ConclusionsThe OS benefit from first-line treatment with dacomitinib versus gefitinib was maintained after extended follow-up in patients with advanced NSCLC withEGFR-activating mutations.ClinicalTrials.govNCT01774721 (registered 24 January 2013).
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Dermatitis | Dermatology | Drugs & Pharmacology | Japan Health | Lung Cancer | Non-Small Cell Lung Cancer | Study